PX1 Research provides certified, high-purity Bronchogen (Ala-Asp-Glu-Leu) for qualified research institutions investigating pulmonary epithelial dynamics, surfactant protein transcription, and respiratory peptide signaling. Each lot undergoes rigorous third-party analytical testing to verify chemical identity, sequence integrity, and endotoxin compliance for reliable experimental reproducibility.
PX1 Research provides certified, high-purity Bronchogen (Ala-Asp-Glu-Leu) for qualified research institutions investigating pulmonary epithelial dynamics, surfactant protein transcription, and respiratory peptide signaling. Each lot undergoes rigorous third-party analytical testing to verify chemical identity, sequence integrity, and endotoxin compliance for reliable experimental reproducibility.
PX1 Research serves as a primary domestic USA supplier of high-purity Bronchogen (Ala-Asp-Glu-Leu) for in vitro and animal models investigating pulmonary surfactant expression. Every batch is synthesized in GMP-compliant facilities and accompanied by independent third-party RP-HPLC and Mass Spectrometry validation, confirming purity above 98% alongside verified low endotoxin specifications.
When sourcing peptides for specialized cellular assays, investigators require unambiguous analytical verification to prevent artifactual data caused by chemical impurities or bacterial lipopolysaccharide (LPS) contamination. PX1 Research delivers transparent, lot-specific testing data to support rigorous scientific inquiry into respiratory tissue homeostasis.
Bronchogen is a synthetic tetrapeptide consisting of the amino acid sequence L-alanyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine (Ala-Asp-Glu-Leu, or ADEL). Belonging to the class of short peptide bioregulators, its low molecular weight (approximately 446.45 g/mol) allows it to interact with nucleosomal structures and cellular targets in preclinical experimental models.
In laboratory settings, scientists examine bronchogen to understand how short peptide sequences cross cellular membranes without requiring complex active transport channels. The acidic carboxyl groups provided by the aspartic and glutamic acid residues contribute to specific electrostatic interactions with basic histone proteins and nucleic acid sequences.
Pulmonary surfactants—primarily surfactant proteins A, B, C, and D (SP-A, SP-B, SP-C, and SP-D)—are essential lipid-protein complexes produced by alveolar type II (AT2) epithelial cells. These proteins reduce alveolar surface tension and mediate innate immune defense within the lung microenvironment. Preclinical studies suggest that short peptide bioregulators like Bronchogen modulate the transcriptional activity of genes encoding these key surfactant proteins.
In vitro assays using primary bronchial epithelial cultures and AT2 cell lines indicate that exposure to Bronchogen induces altered mRNA expression profiles for structural and functional surfactant markers. Researchers investigating cellular stress models have observed that peptide application correlates with maintained expression of SP-B and SP-C under challenged culture conditions, suggesting a protective regulatory mechanism at the genomic level.
The primary mechanism of action explored in short peptide research involves direct interaction with DNA promoter regions and histone proteins. In silico and cell-free binding assays demonstrate that tetrapeptides like Ala-Asp-Glu-Leu can fit into the major and minor grooves of double-stranded DNA, potentially destabilizing tight chromatin packing.
By modulating local chromatin structure, Bronchogen may increase the accessibility of specific promoter sites to RNA polymerase II and tissue-specific transcription factors. This epigenetic mechanism is detailed across wider literature in our epigenetic peptides research guide, which examines how low-molecular-weight peptides participate in gene-specific transcriptional activation without integrating into the genomic sequence.
Short bioregulatory peptides share structural design principles but demonstrate target-tissue specificity in animal models. When evaluating candidate compounds for cellular regulation studies, researchers frequently compare Bronchogen against other tissue-targeted short peptides.
While Bronchogen is studied primarily for pulmonary and bronchial epithelial applications, related short peptides target distinct physiological pathways. For instance, epitalon (Ala-Glu-Asp-Gly) is investigated for pineal gland regulation and telomerase expression, whereas thymogen (Glu-Trp) is targeted toward T-cell differentiation and immune signaling assays. Investigators selecting compounds from our full research peptide catalog often analyze these structural variations to evaluate differential gene expression across specific cell lines.
Procuring research-grade peptides requires stringent vendor evaluation to ensure experimental reliability. Low-grade peptides containing unreacted amino acid fragments, trifluoroacetate (TFA) salts, or heavy metals can compromise cellular assays, induce cytotoxicity, or yield inconsistent gene expression data.
PX1 Research addresses these risks through strict domestic production protocols. All compounds offered through our laboratory supply portal undergo rigorous quality control measures. We mandate full lot traceability, high-resolution mass verification, and comprehensive purity profiling before releasing any batch for laboratory use.
To guarantee chemical identity and purity, every lot of Bronchogen supplied by PX1 Research is submitted to an independent ISO 17025 accredited laboratory for analysis. Verification relies on two core analytical methodologies:
1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Measures chemical purity by separating the target tetrapeptide from synthesis byproducts, establishing a purity profile of ≥98%. 2. Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact molecular mass and peptide sequence identity, ensuring no incorrect amino acid deletions or truncations are present.
Furthermore, because bacterial endotoxins (lipopolysaccharides) can stimulate Toll-like receptor 4 (TLR4) on bronchial epithelial cells and confound inflammatory biomarker studies, PX1 Research subjects all peptide lots to Chromogenic Reagent Kinetic LAL Testing (USP <85>). Endotoxin levels are strictly controlled to remain below industry-standard thresholds for in vitro research.
Bronchogen is supplied as a sterile, lyophilized (freeze-dried) powder to maintain molecular stability during storage and transport. Reconstitution should be performed inside a verified laminar flow cabinet using sterile techniques.
For standard cell culture and biochemical assays, reconstitute the lyophilized powder using Bacteriostatic Water or Sterile Normal Saline (0.9% NaCl). Gentle agitation by swirling is recommended; vortexing should be minimized to avoid mechanical shear stress on peptide bonds. For precise molar calculations and stock solution preparation guidance, researchers can refer to our peptide research resource hub.
Lyophilized Bronchogen must be stored at -20°C upon receipt for long-term stability. Under dry, desiccated conditions at -20°C, the lyophilized peptide remains stable for up to 24 months. Exposure to ambient moisture and room temperature should be minimized during handling.
Once reconstituted into aqueous solution, aliquots should be prepared immediately to avoid repeated freeze-thaw cycles, which degrade peptide integrity. Reconstituted liquid stock solutions should be stored at -80°C for extended study protocols or at 4°C for short-term use (not exceeding 7 to 14 days, depending on solvent purity and container inertness).
What is Bronchogen defined as in scientific literature?
Bronchogen is a synthetic short tetrapeptide composed of L-alanine, L-aspartic acid, L-glutamic acid, and L-leucine (Ala-Asp-Glu-Leu). It is studied in preclinical research models for its potential role in regulating surfactant protein expression and bronchial epithelial cell function.
How does PX1 Research verify the purity of Bronchogen?
Every lot of Bronchogen undergoes third-party testing via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify purity levels of ≥98%, alongside Mass Spectrometry (MS) to confirm molecular identity.
What are the endotoxin limits for research-grade Bronchogen?
PX1 Research conducts kinetic LAL endotoxin testing (USP <85>) on all peptide lots to ensure endotoxin levels are maintained well below standard thresholds required for sensitive in vitro and cellular assays.
Can Bronchogen be ordered for human clinical use or patient therapy?
No. Bronchogen provided by PX1 Research is strictly designated for laboratory research use only (RUO) by qualified scientific personnel. It is not intended for human or animal diagnostic, therapeutic, or clinical application.
Which solvents are recommended for reconstituting lyophilized Bronchogen?
Lyophilized Bronchogen solubilizes readily in sterile water, sterile normal saline (0.9% NaCl), or phosphate-buffered saline (PBS). Solvents should be chosen based on the specific requirements of the downstream in vitro or cell culture assay.
How should reconstituted Bronchogen solutions be stored?
Reconstituted stock solutions should be divided into single-use aliquots to prevent freeze-thaw degradation and stored at -80°C for long-term storage or 4°C for immediate short-term handling.
Does PX1 Research provide batch-specific Certificates of Analysis (COA)?
Yes. Every order of Bronchogen includes access to a lot-specific Certificate of Analysis detailing HPLC purity chromatograms, mass spectrum verification, and endotoxin assay results.
How does Bronchogen compare to other peptide bioregulators like Epitalon or Thymogen?
While all three are short regulatory peptides, Bronchogen (Ala-Asp-Glu-Leu) is studied specifically in the context of pulmonary and airway epithelial target tissues, whereas Epitalon targets neuroendocrine models and Thymogen is investigated in immune system assays.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.